Dyspnea Market Report 2026

Dyspnea Market Overview

• Dyspnea market size has reached to $6.73 billion in 2025 • Expected to grow to $9.5 billion in 2030 at a compound annual growth rate (CAGR) of 7.1% • Growth Driver: Increasing Prevalence Of Respiratory Diseases Driving Market Growth • Market Trend: Phosphodiesterase (PDE) Inhibitors In Drug Development • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Dyspnea Market?

Dyspnea refers to difficulty breathing or shortness of breath. It is a medical term used to describe the sensation of not getting enough air into the lungs, which can manifest as tightness in the chest, gasping for air, or working harder to breathe. Dyspnea is utilized through various clinical methods and tools to evaluate its severity, impact on daily life, and underlying causes. The main treatment types for the dyspnea include supplemental oxygen therapy and relaxation therapy. Supplemental oxygen therapy involves administering oxygen to increase blood oxygen levels, aiding breathing in patients with respiratory conditions or those recovering from severe illnesses. The drug classes used for treatment include anti-anxiety medications, antibiotics, anticholinergic agents, corticosteroids, and others. These drugs are administered through various routes, such as oral, inhalation, and other methods. They are used by different end users, including hospitals, home care, specialty clinics, ambulatory services, and other healthcare settings.

What Is The Dyspnea Market Growth Forecast?

The dyspnea market size is expected to see strong growth in the next few years. It will grow to $9.5 billion in 2030 at a compound annual growth rate (CAGR) of 7.1%. The growth in the forecast period can be attributed to portable oxygen systems demand, remote respiratory monitoring, personalized dyspnea management, homecare expansion, digital symptom tracking. Major trends in the forecast period include increasing use of oxygen therapy devices, rising adoption of home-based respiratory care, growing focus on symptom management therapies, integration of breathing and relaxation techniques, improved diagnostic assessment of respiratory disorders.

What Is The Driver Of The Dyspnea Market?

The increasing prevalence of respiratory diseases is expected to propel the growth of the dyspnea market going forward. Respiratory diseases are conditions that affect the lungs and respiratory system, impairing airflow and reducing oxygen exchange. The prevalence of respiratory diseases is rising due to air pollution, smoking, environmental toxins, climate change, and growing susceptibility in aging populations. The dyspnea market supports this trend because dyspnea serves as a critical indicator of impaired lung function, helping clinicians diagnose respiratory conditions, guide treatment plans, and monitor disease progression. For instance, in June 2024, according to the Australian Institute of Health and Welfare, an Australia-based government agency, in 2023, COPD contributed to 3.6% of the total disease burden and accounted for 50% of the overall burden of respiratory diseases. In 2022, COPD was the primary cause of 7,691 deaths, with a mortality rate of 29.6 per 100,000 people, representing 4.0% of all deaths. Therefore, the increasing prevalence of respiratory diseases is driving the growth of the dyspnea industry.

Key Players In The Global Dyspnea Market

Major companies operating in the dyspnea market are Pfizer Inc., Merck And Co. Inc., Bayer AG, Sanofi S.A., AstraZeneca, Novartis AG, GlaxoSmithKline, Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim, Amneal Pharmaceuticals LLC, Lupin Ltd, Inogen Inc, Fisher & Paykel Healthcare, ResMed Inc, Koninklijke Philips N.V, Masimo Corporation, Breas Medical, PARI Medical Holding GmbH, BMC Medical, Hamilton Medical, Nihon Kohden Corporation, Cipla Inc

Global Dyspnea Market Trends and Insights

Major companies operating in the dyspnea market are focusing on developing new drug therapies such as phosphodiesterase (PDE) inhibitors to improve treatment efficacy, reduce respiratory symptoms, and provide better relief for patients with chronic breathing difficulties. A phosphodiesterase (PDE) inhibitor is a medication that blocks PDE enzymes, increasing intracellular cyclic AMP or cyclic GMP levels, which promotes bronchodilation, reduces inflammation, and enhances overall respiratory function. For instance, in May 2024, Verona Pharma Plc, a UK-based biopharmaceutical company, announced preparations for the anticipated U.S. launch of ensifentrine, a first-in-class dual PDE3/4 inhibitor for chronic obstructive pulmonary disease (COPD), expected in Q3 2024 pending FDA approval. Ensifentrine, delivered via nebulization, has shown significant reductions in COPD exacerbation rates and meaningful improvements in dyspnea in Phase III trials, and Verona secured $650 million in financing to support its commercial rollout and further development, including a planned Phase II fixed-dose combination trial with glycopyrrolate for maintenance COPD therapy.

What Are Latest Mergers And Acquisitions In The Dyspnea Market?

In October 2025, Merck & Co. Inc., a US-based biopharmaceutical company, acquired Verona Pharma plc for about $10 billion. With this acquisition, Merck aimed to strengthen and diversify its cardiopulmonary portfolio by adding a novel, first-in-class COPD treatment. Verona Pharma Plc is a UK-based biopharmaceutical company that develops a treatment that has been clinically proven to improve dyspnea.

What Defines the Dyspnea Market?

The dyspnea market consists of revenues earned by entities by providing services such as pulmonary rehabilitation, oxygen therapy, respiratory monitoring, telemedicine consultations, and patient education programs. The market value includes the value of related goods sold by the service provider or included within the service offering. The dyspnea market also includes sales of products such as bronchodilators, ventilators, nebulizers, portable oxygen concentrators, and pulmonary function testing devices. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The IT market is segmented into IT services, computer hardware, telecom, and software products.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Dyspnea Market Report 2026?

The dyspnea market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the dyspnea industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.